(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Creative Realities, American Public Education, and GoPro.

The three biggest losers today are Corbus Pharmaceuticals Holdings, Identiv, and Ebix.

Winners today

1. Creative Realities (CREXW) – 40.62%

NASDAQ ended the session with Creative Realities jumping 40.62% to $0.01 on Thursday while NASDAQ rose 0.08% to $13,650.41.

Yearly Top and Bottom Value

Creative Realities’s stock is valued at $0.01 at 01:32 EST, way higher than its 52-week high of $0.01.

More news about Creative Realities.

2. American Public Education (APEI) – 22.33%

American Public Education, Inc., together with its subsidiaries, provides online and campus-based postsecondary education and career learning. It operates through three segments: American Public University System, Rasmussen University, and Hondros College of Nursing. The company offers 136 degree programs and 115 certificate programs in various fields of study, including nursing, public health, public administration, and business administration. It also provides nursing-and health sciences-focused postsecondary education, diploma in practical nursing, and an associate degree in nursing. The company was incorporated in 1991 and is headquartered in Charles Town, West Virginia.

NASDAQ ended the session with American Public Education rising 22.33% to $5.26 on Thursday while NASDAQ rose 0.08% to $13,650.41.

Earnings Per Share

As for profitability, American Public Education has a trailing twelve months EPS of $-3.79.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.39%.

Sales Growth

American Public Education’s sales growth is 1.8% for the ongoing quarter and negative 0.6% for the next.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend yield is 18.23%.

More news about American Public Education.

3. GoPro (GPRO) – 15.86%

GoPro, Inc. develops and sells cameras, mountable and wearable accessories, and subscription services and software in the Americas, Europe, the Middle East, Africa, the Asia and Pacific region, and internationally. The company provides cloud connected HERO11 Black, HERO11 Black Mini, HERO10 Black, HERO10 Black Bones, HERO9 Black, and HERO8 Black waterproof cameras; MAX, a 360-degree waterproof camera; GoPro, a subscription service that includes full access to the Quik app, cloud storage supporting source video and photo quality, camera replacement, and damage protection; Quik subscription offers access to editing tools, which allows users to edit photos, videos, and create cinematic stories; and Quik app, a mobile app that enable users to get their favorite photos and videos with footage from any phone or camera. It also offers mounts and accessories comprising equipment-based mounts consisting of helmet, handlebar, roll bar, and tripod mounts that enable consumers to wear the mount on their bodies, such as wrist housings, magnetic swivel clips, chest harnesses, and head straps; media, display, and light mods; spare batteries, dive filters, and charging accessories and cables; and lifestyle gears. In addition, the company provides mobile and web applications that provides media workflow for archiving, editing, multi-clip story creation, and sharing content on the fly. GoPro, Inc. markets and sells its products through retailers and wholesale distributors, as well as through its GoPro.com website. The company was formerly known as Woodman Labs, Inc. and changed its name to GoPro, Inc. in February 2014. GoPro, Inc. was founded in 2002 and is headquartered in San Mateo, California.

NASDAQ ended the session with GoPro jumping 15.86% to $3.11 on Thursday while NASDAQ rose 0.08% to $13,650.41.

Earnings Per Share

As for profitability, GoPro has a trailing twelve months EPS of $-0.17.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.57%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is a negative 89.5% and a negative 58.3%, respectively.

Previous days news about GoPro

• Gopro (gpro) reports Q3 earnings: what key metrics have to say. According to Zacks on Wednesday, 8 November, "For the quarter ended September 2023, GoPro (GPRO Quick QuoteGPRO – Free Report) reported revenue of $294.3 million, down 3.6% over the same period last year. ", "Here is how GoPro performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"

More news about GoPro.

4. CRISPR Therapeutics AG (CRSP) – 13.57%

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

NASDAQ ended the session with CRISPR Therapeutics AG rising 13.57% to $58.58 on Thursday, after five sequential sessions in a row of gains. NASDAQ jumped 0.08% to $13,650.41, after five consecutive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, CRISPR Therapeutics AG has a trailing twelve months EPS of $-5.3.

More news about CRISPR Therapeutics AG.

5. Upwork (UPWK) – 11.06%

Upwork Inc., together with its subsidiaries, operates a work marketplace that connects businesses with various independent professionals and agencies in the United States, India, the Philippines, and internationally. The company's work marketplace provides access to talent with various skills across a range of categories, including sales and marketing, customer service, data science and analytics, design and creative, web, mobile, and software development. Its work marketplace also enables clients to streamline workflows, such as talent sourcing, outreach, and contracting. The company's work marketplace offers access to various functionalities for remote engagements with talent, including communication and collaboration, ability to receive talent invoices through their work marketplace, and payment protection. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Enterprise, and Upwork Payroll, as well as managed and internet escrow agency services. The company was formerly known as Elance-oDesk, Inc. and changed its name to Upwork Inc. in May 2015. Upwork Inc. was incorporated in 2013 and is headquartered in San Francisco, California.

NASDAQ ended the session with Upwork rising 11.06% to $13.35 on Thursday, after four successive sessions in a row of gains. NASDAQ jumped 0.08% to $13,650.41, after five consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Upwork has a trailing twelve months EPS of $-0.5.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.18%.

Previous days news about Upwork

• Here's what key metrics tell us about upwork (upwk) Q3 earnings. According to Zacks on Wednesday, 8 November, "Here is how Upwork performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"

More news about Upwork.

6. EHang Holdings Limited (EH) – 9%

EHang Holdings Limited operates as an autonomous aerial vehicle (AAV) technology platform company in the People's Republic of China, North America, East Asia, Europe, West Asia, and internationally. It designs, develops, manufactures, sells, and operates AAVs, as well as their supporting systems and infrastructure for a range of industries and applications, including passenger transportation, logistics, smart city management, and aerial media solutions. EHang Holdings Limited has a strategic partnership with Shenzhen Expressway Operation Development Company Limited. The company was incorporated in 2014 and is headquartered in Guangzhou, the People's Republic of China.

NASDAQ ended the session with EHang Holdings Limited rising 9% to $14.23 on Thursday while NASDAQ rose 0.08% to $13,650.41.

Earnings Per Share

As for profitability, EHang Holdings Limited has a trailing twelve months EPS of $-0.82.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -170.28%.

More news about EHang Holdings Limited.

7. Conifer Holdings (CNFR) – 8.82%

Conifer Holdings, Inc., an insurance holding company, engages in the sale of property and casualty insurance products. It offers insurance coverage in specialty commercial and personal product lines. The company underwrites various specialty insurance products, including property, general liability, liquor liability, automobile, and homeowners and dwelling policies. It serves the commercial insurance needs of owner-operated businesses in the markets, such as hospitality, which includes restaurants, bars, taverns, and bowling centers, as well as small grocery and convenience stores; artisan contractors comprising plumbers, painters, carpenters, electricians, and other independent contractors; and security service providers, including companies that provide security guard services, security alarm products and services, and private investigative services. The company also offers specialty homeowners insurance products, such as low- value dwelling insurance tailored for owners of lower valued homes in Illinois, Indiana, Louisiana, and Texas; and wholesale agency services comprising commercial and personal lines insurance products for its insurance company subsidiaries, as well as third party insurers. Conifer Holdings, Inc. markets and sells its insurance products through a network of approximately 4,900 independent agents in 50 states in the United States. The company was incorporated in 2009 and is headquartered in Troy, Michigan.

NASDAQ ended the session with Conifer Holdings jumping 8.82% to $1.11 on Thursday, following the last session’s upward trend. NASDAQ jumped 0.08% to $13,650.41, after five successive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Conifer Holdings has a trailing twelve months EPS of $-0.15.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.62%.

Yearly Top and Bottom Value

Conifer Holdings’s stock is valued at $1.11 at 01:32 EST, way under its 52-week high of $2.08 and way above its 52-week low of $0.91.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 115.4% and 120%, respectively.

Moving Average

Conifer Holdings’s value is way below its 50-day moving average of $1.25 and way under its 200-day moving average of $1.52.

More news about Conifer Holdings.

8. DZS (DZSI) – 8.28%

DZS Inc. provides network access solutions and communications platforms for service provider and enterprise networks in the Americas, Europe, the Middle East, Africa, and Asia. It offers mobile transport products, including standard Ethernet/IP or multiprotocol label switching interfaces and interoperate to mobile operators that enables them to upgrade their mobile fronthaul/backhaul systems and migrate to 5G and beyond; broadband access products, which consists of switching and routing products to carriers and service providers to connect residential and business customers; and connected premises products, comprising of indoor/outdoor optical network terminal gateways. The company also provides software and services, which consists of software defined networking orchestration solutions, network function virtualization, and professional and technical support services. It has a strategic partnership with Quanta Cloud Technology; and Plume Design, Inc. The company was formerly known as DASAN Zhone Solutions, Inc. and changed its name to DZS Inc. in August 2020. The company was founded in 1996 and is based in Plano, Texas.

NASDAQ ended the session with DZS jumping 8.28% to $1.70 on Thursday while NASDAQ rose 0.08% to $13,650.41.

Earnings Per Share

As for profitability, DZS has a trailing twelve months EPS of $-1.77.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.81%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 17.9%, now sitting on 389.46M for the twelve trailing months.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend yield is 0.19%.

More news about DZS.

9. VerifyMe (VRME) – 8.08%

VerifyMe, Inc., together with its subsidiary, PeriShip Global, LLC, operates as a technology solutions provider that specializes in products to connect brands with consumers and providing brands with end-to-end logistics management for their products. The company operates through two segments, VerifyMe Solutions and PeriShip Global Solutions. The VerifyMe Solutions segment offers technology solutions to connect brands with consumers allowing brand owners to gather business intelligence while engaging directly with their consumers. Its solutions provide brand protection and supply chain functions, such as counterfeit prevention, traceability, consumer engagement solutions, and authentication for labels, packaging, and products, as well as tamper-proof labels. The PeriShip Global Solutions segment offers predictive analytics for optimizing delivery of time and temperature sensitive perishable products. This segment's products include PeriTrack customer dashboard, an integrated web portal tool gives its customers an in-depth look at their shipping activities based on real-time data. It also provides call center, pre-transit, post-delivery, and weather/traffic services. The company has a strategic partnership with INX International Ink Company. The company was formerly known as LaserLock Technologies, Inc. and changed its name to VerifyMe, Inc. in July 2015. VerifyMe, Inc. was incorporated in 1999 and is headquartered in Lake Mary, Florida.

NASDAQ ended the session with VerifyMe jumping 8.08% to $1.07 on Thursday while NASDAQ rose 0.08% to $13,650.41.

Earnings Per Share

As for profitability, VerifyMe has a trailing twelve months EPS of $-0.18.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.44%.

Moving Average

VerifyMe’s worth is below its 50-day moving average of $1.16 and way below its 200-day moving average of $1.48.

Earnings Before Interest, Taxes, Depreciation, and Amortization

VerifyMe’s EBITDA is -17.11.

Volatility

VerifyMe’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.93%, a negative 0.70%, and a positive 2.61%.

VerifyMe’s highest amplitude of average volatility was 4.93% (last week), 2.23% (last month), and 2.61% (last quarter).

More news about VerifyMe.

10. Cemtrex (CETX) – 7.96%

Cemtrex, Inc. operates as a technology company in the United States and internationally. The company operates through Advanced Technologies and Industrial Services segments. The Advanced Technologies segment provides Internet of Things products and smart devices under the SmartDesk name for mobile, web, virtual and augmented reality, wearables, and television markets; and security and video surveillance solutions, and virtual and augmented reality solutions for various commercial and industrial applications. This segment also offers browser-based video monitoring systems and analytics-based recognition systems, cameras, servers, and access control systems for security and surveillance in industrial and commercial facilities, federal prisons, hospitals, universities, schools, and federal and state government offices. The Industrial Services segment provides single-source services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly; installs high precision equipment in various industrial markets comprising automotive, printing and graphics, industrial automation, packaging, chemicals and others; and provides maintenance and contracting solutions for the machinery, packaging, printing, chemical, and other manufacturing markets. The company was formerly known as Diversified American Holding, Inc. and changed its name to Cemtrex, Inc. in December 2004. Cemtrex, Inc. was incorporated in 1998 and is headquartered in Brooklyn, New York.

NASDAQ ended the session with Cemtrex jumping 7.96% to $5.11 on Thursday, after five consecutive sessions in a row of gains. NASDAQ jumped 0.08% to $13,650.41, after five successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Cemtrex has a trailing twelve months EPS of $-13.09.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -79.2%.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Mar 28, 2017, the estimated forward annual dividend rate is 0.02 and the estimated forward annual dividend yield is 0.81%.

Yearly Top and Bottom Value

Cemtrex’s stock is valued at $5.11 at 01:32 EST, way below its 52-week high of $14.46 and way above its 52-week low of $3.15.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is a negative 271% and positive 94.7% for the next.

More news about Cemtrex.

Losers Today

1. Corbus Pharmaceuticals Holdings (CRBP) – -16.67%

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

NASDAQ ended the session with Corbus Pharmaceuticals Holdings dropping 16.67% to $4.20 on Thursday while NASDAQ jumped 0.08% to $13,650.41.

Earnings Per Share

As for profitability, Corbus Pharmaceuticals Holdings has a trailing twelve months EPS of $-10.98.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -156.6%.

More news about Corbus Pharmaceuticals Holdings.

2. Identiv (INVE) – -14.45%

Identiv, Inc. operates as a security technology company that secures things, data, and physical places in the Americas, Europe, the Middle East, and the Asia-Pacific. The company operates in two segments, Identity and Premises. The Identity segment offers products and solutions that enables secure access to information serving the logical access and cyber security markets, as well as protecting connected objects and information using radio-frequency identification embedded security. The Premises segment provides solutions for premises security market, such as access control, video surveillance, analytics, audio, access readers, and identities to government facilities, schools, utilities, hospitals, stores, and apartment buildings. The company sells its products through dealers, systems integrators, value added resellers, and resellers. The company was formerly known as Identive Group, Inc. and changed its name to Identiv, Inc. in May 2014. Identiv, Inc. was founded in 1990 and is headquartered in Fremont, California.

NASDAQ ended the session with Identiv falling 14.45% to $5.15 on Thursday, after two consecutive sessions in a row of losses. NASDAQ jumped 0.08% to $13,650.41, after five consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Identiv has a trailing twelve months EPS of $-0.19.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.07%.

Yearly Top and Bottom Value

Identiv’s stock is valued at $5.15 at 01:32 EST, way below its 52-week high of $10.35 and above its 52-week low of $5.07.

Volatility

Identiv’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.66%, a negative 1.55%, and a positive 2.82%.

Identiv’s highest amplitude of average volatility was 2.10% (last week), 3.96% (last month), and 2.82% (last quarter).

More news about Identiv.

3. Ebix (EBIX) – -14.07%

Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, cash remittance, and healthcare industries in the United States and internationally. The company develops and deploys insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance solutions. Its EbixCash exchange related products and services include gift cards; travel exchanges services; money transfer services; foreign exchange and outward remittance services; consumer payment services; and on-demand technology to various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setup, customization, training, or consulting. Its risk compliance services cover certificates of insurance creation and tracking; consulting services, such as project management, integration, development, and testing; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.

NASDAQ ended the session with Ebix falling 14.07% to $4.86 on Thursday, after two successive sessions in a row of losses. NASDAQ jumped 0.08% to $13,650.41, after five sequential sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Ebix has a trailing twelve months EPS of $1.09.

PE Ratio

Ebix has a trailing twelve months price to earnings ratio of 4.45. Meaning, the purchaser of the share is investing $4.45 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.64%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Ebix’s EBITDA is 42.8.

Moving Average

Ebix’s value is way below its 50-day moving average of $10.08 and way below its 200-day moving average of $17.00.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Dec 1, 2022, the estimated forward annual dividend rate is 0.3 and the estimated forward annual dividend yield is 4.84%.

More news about Ebix.

4. Casa Systems (CASA) – -12.28%

Casa Systems, Inc., a communications technology company, provides solutions for next-generation physical, virtualized, and cloud native architectures for cable broadband, fixed-line broadband, and wireless networks in North America, Latin America, the Asia-Pacific, Europe, the Middle East, and Africa. It offers converged cable access platforms; wireless network core products, such as virtual evolved packet and 5G core products, as well as small cell solutions, axyom element management system, and fixed wireless access devices; and virtual, centralized, and distributed deployment, and bandwidth capacity expansion systems. The company provides optical access solutions, virtualized broadband network gateway router and multiservice router, fiber extension, and residential broadband gateways; and machine-to-machine and industrial internet of things routers. Casa Systems, Inc. was incorporated in 2003 and is headquartered in Andover, Massachusetts.

NASDAQ ended the session with Casa Systems falling 12.28% to $0.55 on Thursday while NASDAQ jumped 0.08% to $13,650.41.

Earnings Per Share

As for profitability, Casa Systems has a trailing twelve months EPS of $-1.16.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -535.81%.

More news about Casa Systems.

5. Aspen Group (ASPU) – -11.76%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group dropping 11.76% to $0.15 on Thursday, following the last session’s upward trend. NASDAQ rose 0.08% to $13,650.41, after five successive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

Volume

Today’s last reported volume for Aspen Group is 16443 which is 45.39% below its average volume of 30110.

More news about Aspen Group.

6. Virgin Galactic (SPCE) – -8.71%

Virgin Galactic Holdings, Inc. focuses on the development, manufacture, and operation of spaceships and related technologies for conducting commercial human spaceflight and flying commercial research and development payloads into space. It is also involved in the ground and flight testing, and post-flight maintenance of its spaceflight system vehicles. The company serves private individuals, researchers, and government agencies. Virgin Galactic Holdings, Inc. was founded in 2017 is headquartered in Las Cruces, New Mexico.

NYSE ended the session with Virgin Galactic sliding 8.71% to $1.59 on Thursday while NYSE fell 0.16% to $15,364.27.

Earnings Per Share

As for profitability, Virgin Galactic has a trailing twelve months EPS of $-2.13.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -103.98%.

Moving Average

Virgin Galactic’s value is way below its 50-day moving average of $2.13 and way under its 200-day moving average of $3.80.

Previous days news about Virgin Galactic

• : Virgin Galactic to cut staff to focus on lower-cost delta ships. According to MarketWatch on Wednesday, 8 November, "Commercial space-flight operator Virgin Galactic Holdings Inc. on Tuesday said it would be cutting staff and costs outside of its Delta spacecraft program, which it expects to bring lower costs and more profit. "
• Virgin Galactic to cut staff to focus on lower-cost delta spacecraft. According to MarketWatch on Wednesday, 8 November, "Commercial space-flight operator Virgin Galactic Holdings Inc. on Tuesday said it would cut staff in an effort to focus on developing its new class of Delta spacecraft that are expected to cost less and bring more profit."

More news about Virgin Galactic.

7. FibroGen (FGEN) – -8.4%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen sliding 8.4% to $0.51 on Thursday, after two sequential sessions in a row of losses. NASDAQ jumped 0.08% to $13,650.41, after five sequential sessions in a row of gains, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1015.79%.

Moving Average

FibroGen’s worth is way below its 50-day moving average of $0.79 and way under its 200-day moving average of $11.11.

Earnings Before Interest, Taxes, Depreciation, and Amortization

FibroGen’s EBITDA is 0.05.

Previous days news about FibroGen

• Fibrogen (fgen) Q3 earnings: taking a look at key metrics versus estimates. According to Zacks on Monday, 6 November, "For the quarter ended September 2023, FibroGen (FGEN Quick QuoteFGEN – Free Report) reported revenue of $40.13 million, up 155% over the same period last year. ", "Here is how FibroGen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"

More news about FibroGen.

8. Riot Blockchain (RIOT) – -7.85%

Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. It operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. The company also provides co-location services for institutional-scale bitcoin mining companies; and critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners. In addition, it engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy; operation of data centers; and maintenance/management of computing capacity. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain dropping 7.85% to $10.20 on Thursday while NASDAQ rose 0.08% to $13,650.41.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-1.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.82%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 8.3% and 72.2%, respectively.

Yearly Top and Bottom Value

Riot Blockchain’s stock is valued at $10.20 at 01:32 EST, way under its 52-week high of $20.65 and way higher than its 52-week low of $3.25.

More news about Riot Blockchain.

9. DiaMedica Therapeutics (DMAC) – -7.32%

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

NASDAQ ended the session with DiaMedica Therapeutics sliding 7.32% to $2.28 on Thursday, after two consecutive sessions in a row of losses. NASDAQ rose 0.08% to $13,650.41, after five successive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, DiaMedica Therapeutics has a trailing twelve months EPS of $-0.62.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -33.98%.

More news about DiaMedica Therapeutics.

10. Edesa Biotech (EDSA) – -7.27%

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

NASDAQ ended the session with Edesa Biotech falling 7.27% to $3.06 on Thursday while NASDAQ jumped 0.08% to $13,650.41.

Earnings Per Share

As for profitability, Edesa Biotech has a trailing twelve months EPS of $-2.45.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -96.18%.

Moving Average

Edesa Biotech’s value is way below its 50-day moving average of $4.71 and way below its 200-day moving average of $6.64.

Yearly Top and Bottom Value

Edesa Biotech’s stock is valued at $3.06 at 01:32 EST, way below its 52-week high of $19.67 and way higher than its 52-week low of $2.46.

Volume

Today’s last reported volume for Edesa Biotech is 32884 which is 58.11% below its average volume of 78510.

More news about Edesa Biotech.

Stay up to date with our winners and losers daily report